Prime Medicine, Inc. (PRME) Research

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

Market snapshot

Symbol
PRME
Price
$3.23
Day change
+2.22%
Market cap
$583.4M
P/E ratio
-2.88x
52-week range
1.77-6.94
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$17.25

Peer companies

  • Bicara Therapeutics Inc. Common Stock (BCAX)
  • EyePoint Pharmaceuticals, Inc. (EYPT)
  • Kura Oncology, Inc. (KURA)
  • Maravai LifeSciences Holdings, Inc. (MRVI)
  • ProKidney Corp. (PROK)
  • Replimune Group, Inc. (REPL)
  • Rezolute, Inc. (RZLT)
  • Septerna, Inc. (SEPN)

Recent insider activity

  • Schenkein David P — A-Award (75000 shares) on 2026-06-05
  • Marrazzo Jeffrey D — A-Award (75000 shares) on 2026-06-05
  • NELSEN ROBERT — A-Award (75000 shares) on 2026-06-05
  • Kelly Michael Aaron — A-Award (75000 shares) on 2026-06-05
  • Foster-Cheek Kaye I — A-Award (75000 shares) on 2026-06-05

Open Prime Medicine, Inc. (PRME) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.